Vestal Point Capital
Latest statistics and disclosures from Vestal Point Capital's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0001974915
Tip: Access up to 7 years of quarterly data
Positions held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Vestal Point Capital
Vestal Point Capital holds 60 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 11.9 | $160M | 1.5M | 106.73 |
|
|
| Cytokinetics Com New (CYTK) | 8.4 | $112M | 2.1M | 54.18 |
|
|
| Ascendis Pharma A/S Sponsored Adr (ASND) | 7.6 | $102M | 750k | 136.38 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 5.5 | $74M | 1.8M | 41.10 |
|
|
| Globus Medical Cl A (GMED) | 4.6 | $62M | 900k | 68.49 |
|
|
| Insmed Com Par $.01 (INSM) | 3.7 | $50M | 750k | 67.00 |
|
|
| BeiGene Sponsored Adr (BGNE) | 3.7 | $50M | 350k | 142.67 |
|
|
| Soleno Therapeutics (SLNO) | 3.7 | $49M | 1.2M | 40.80 |
|
|
| EXACT Sciences Corporation (EXAS) | 2.9 | $39M | 925k | 42.25 |
|
|
| Arcellx Common Stock (ACLX) | 2.8 | $37M | 675k | 55.19 |
|
|
| Immatics NV SHS (IMTX) | 2.4 | $32M | 2.8M | 11.62 |
|
|
| Janux Therapeutics (JANX) | 2.3 | $30M | 725k | 41.89 |
|
|
| Astria Therapeutics (ATXS) | 2.2 | $30M | 3.3M | 9.10 |
|
|
| Kalvista Pharmaceuticals (KALV) | 2.0 | $27M | 2.3M | 11.78 |
|
|
| Savara (SVRA) | 2.0 | $26M | 6.5M | 4.03 |
|
|
| Iteos Therapeutics (ITOS) | 1.9 | $26M | 1.8M | 14.84 |
|
|
| Applied Therapeutics (APLT) | 1.9 | $25M | 5.4M | 4.67 |
|
|
| Axsome Therapeutics (AXSM) | 1.8 | $24M | 300k | 80.50 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.6 | $22M | 560k | 39.27 |
|
|
| Liquidia Corp Com New (LQDA) | 1.6 | $22M | 1.8M | 12.00 |
|
|
| Alx Oncology Hldgs (ALXO) | 1.6 | $22M | 3.6M | 6.03 |
|
|
| uniQure NV SHS (QURE) | 1.6 | $21M | 4.8M | 4.48 |
|
|
| Bristol Myers Squibb (BMY) | 1.5 | $21M | 500k | 41.53 |
|
|
| Xenon Pharmaceuticals (XENE) | 1.5 | $21M | 525k | 38.99 |
|
|
| Praxis Precision Medicines Com New (PRAX) | 1.4 | $18M | 440k | 41.36 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 1.3 | $17M | 1.3M | 13.78 |
|
|
| Inari Medical Ord (NARI) | 1.3 | $17M | 350k | 48.15 |
|
|
| Dianthus Therapeutics (DNTH) | 1.2 | $16M | 600k | 25.88 |
|
|
| Solid Biosciences Com New (SLDB) | 1.1 | $15M | 2.7M | 5.67 |
|
|
| Lexeo Therapeutics (LXEO) | 1.0 | $14M | 840k | 16.04 |
|
|
| Apellis Pharmaceuticals (APLS) | 1.0 | $13M | 335k | 38.36 |
|
|
| Immunome (IMNM) | 0.9 | $12M | 1.0M | 12.10 |
|
|
| Denali Therapeutics (DNLI) | 0.9 | $12M | 500k | 23.22 |
|
|
| Nurix Therapeutics (NRIX) | 0.8 | $10M | 500k | 20.87 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.7 | $9.8M | 2.1M | 4.66 |
|
|
| BioNTech SE Sponsored Ads (BNTX) | 0.6 | $8.0M | 100k | 80.36 |
|
|
| Inspire Med Sys (INSP) | 0.6 | $8.0M | 60k | 133.83 |
|
|
| Pacira Pharmaceuticals (PCRX) | 0.6 | $8.0M | 280k | 28.61 |
|
|
| Dyne Therapeutics (DYN) | 0.6 | $7.9M | 225k | 35.29 |
|
|
| Fulcrum Therapeutics (FULC) | 0.5 | $7.2M | 1.2M | 6.20 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.5 | $6.6M | 620k | 10.69 |
|
|
| Fate Therapeutics (FATE) | 0.5 | $6.6M | 2.0M | 3.28 |
|
|
| Allogene Therapeutics (ALLO) | 0.4 | $5.1M | 2.2M | 2.33 |
|
|
| Passage Bio (PASG) | 0.4 | $4.8M | 6.1M | 0.79 |
|
|
| Voyager Therapeutics (VYGR) | 0.4 | $4.7M | 600k | 7.91 |
|
|
| Galapagos NV Spon Adr (GLPG) | 0.3 | $4.5M | 180k | 24.78 |
|
|
| Zymeworks Del (ZYME) | 0.3 | $3.7M | 440k | 8.51 |
|
|
| Relmada Therapeutics (RLMD) | 0.3 | $3.6M | 1.2M | 3.00 |
|
|
| Macrogenics (MGNX) | 0.3 | $3.4M | 800k | 4.25 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.2 | $3.3M | 890k | 3.74 |
|
|
| Ventyx Biosciences (VTYX) | 0.2 | $3.0M | 1.3M | 2.31 |
|
|
| Ptc Therapeutics I (PTCT) | 0.2 | $2.8M | 90k | 30.58 |
|
|
| Verve Therapeutics (VERV) | 0.2 | $2.4M | 500k | 4.88 |
|
|
| Iovance Biotherapeutics (IOVA) | 0.2 | $2.4M | 300k | 8.02 |
|
|
| Prime Medicine (PRME) | 0.2 | $2.3M | 450k | 5.14 |
|
|
| Chimerix (CMRX) | 0.1 | $1.2M | 1.4M | 0.88 |
|
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.1 | $1.2M | 1.5M | 0.81 |
|
|
| Atara Biotherapeutics Com New | 0.1 | $952k | 112k | 8.50 |
|
|
| Reneo Pharmaceuticals (RPHM) | 0.1 | $823k | 545k | 1.51 |
|
|
| Newamsterdam Pharma Co NV Ordinary Shares (NAMS) | 0.0 | $480k | 25k | 19.21 |
|
Past Filings by Vestal Point Capital
SEC 13F filings are viewable for Vestal Point Capital going back to 2024
- Vestal Point Capital 2024 Q2 filed Aug. 14, 2024